Anatomy of Summertime Upslope Events in Northeastern Colorado: Ammonia (NH) Transport to the Rocky Mountains.

The Transport and Transformation of Ammonia (TRANSAm) airborne field campaign occurred over northeastern Colorado during the summers of 2021 and 2022. A subset of the TRANSAm flights investigated easterly wind conditions capable of moving agricultural emissions of ammonia (NH) through urban areas and into the Rocky Mountains. TRANSAm captured 6 of these events, unveiling important commonalities.

Human plasma-derived alpha -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: A randomized, placebo-controlled proof-of-concept study.

Background: While circulating levels of alpha -proteinase inhibitor (alpha -PI) are typically normal, antiprotease activity appears to be compromised in patients with Type 1 diabetes mellitus (T1DM). Because alpha -PI [human] (alpha -PI[h]) therapy can inhibit pro-inflammatory mediators associated with β-cell destruction and reduced insulin production, it has been proposed for T1DM disease prevention. The aim of this study was to evaluate safety, tolerability, and efficacy of intravenous (IV) alpha -PI[h] in preserving C-peptide production in newly diagnosed T1DM patients.

Variation in pesticide use across crops in California agriculture: Economic and ecological drivers.

Pesticide use is a key component of efficient crop production, but is associated with a suite of costs. Understanding the main drivers of pesticide use will help us target research to develop effective alternatives. Although economic models predict, and empirical tests confirm, that the value of the crop being protected is an important determinant of between-crop variation in pesticide use, previous tests of this prediction have examined only modest numbers of crops and have not assessed the relative importance of crop value versus ecological determinants of pesticide use.

Safety and pharmacokinetics of Alpha-1 MP (Prolastin-C) in Japanese patients with alpha-antitrypsin (AAT) deficiency.

Background: Alpha-Proteinase Inhibitor, Modified Process (Alpha-1 MP) is used for augmentation therapy in alpha1-antitrypsin deficiency (AATD), an extremely rare disease in Japan. Weekly doses of 60 mg/kg Alpha-1 MP have been shown to be safe and well tolerated in non-Japanese subjects, but the safety and pharmacokinetics (PK) have not been evaluated in Japanese subjects. The objectives of this study were to evaluate the safety and PK of 60 mg/kg Alpha-1 MP administered by weekly IV infusions over 8 weeks in Japanese subjects with AATD.